alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
### INTHE UNI TED S TATESCOU RT OFAPPEALS FORTHE FIFTH CIRCU IT

N o. 09- 30702 Su m m ar y Cal endar
UN I TE D S TA TE S OF AM ERI CA, P l ai n t i f f

- A pp el l ee v. JU A N G O N Z A LE S, al so know n as H ugo D ani el

- R odr i gues , al so know n as M i gu elV en t u ra, al so kn ow n as R am on O l arra, al so kn ow n as D an i el H u go, al so k n o w n a s J o s e V e n tu r a -G in e z , a ls o k n o w n a s H u g o D a n ie l, D e fe nda nt
- Appe l l ant
C on soli d a ted w i th N o. 09- 30703 Su m m ar y Cal endar
UN I TE D S TA TE S OF AM ERI CA, P l ai n t i f f

- A pp el l ee v. JU AN G O N ZAL ES, D e fe nda nt
- Appe l l ant

A pp eal s f

rom t h e U n i t ed S t ates D i st ri ctC ou rt f ort he W es t er n D i st r i c tof Loui si ana U SD C N o. 6: 09- C R
- 7- 1 U S D C N o . 6 :09 -C R -5 7 -1 United States Court of App eals Fifth Circuit 

### F I L E D April23, 2010 Lyle W . Cayce Clerk Case: 09-30702 Document: 00511090583 Page: 1 Date Filed: 04/23/2010N o. 09- 30702 c /w N o. 09- 30703

Pursuant to 5 T H C IR . R. 47.5 , the court has determined that this opinionshould not * be publishe d an d is not precede nt except under the limited circu mstance s set forth in 5 T H C IR . R. 47.5 .4. 2 B ef ore JO L L Y , W IE N E R , an d E L R O D , C i rcui tJu dg es . P E R C U R I A M: * Th e Feder alPu bl i c D efenderappoi nt ed t o r epr es ent Juan G onzal es has m o ve d f o rl e av e t o w i t hdr aw andhas f i l e d a b r i e f

i n a c c o r da nc e w i t h A nders v. Ca lif o rn ia , 3 86 U
. S. 7 38 ( 19 67 )
. G o nz al e s has f i l e d a r e s po ns e . O uri nde pe nde nt r e vi e w o f

t he r e c o r d, c o unsel ’ s bri e f, a nd G o nz al e s ’ s r e s po ns e di s c l o s e s no n on frivo l ou s is su e for ap p ea l
. A ccord i n gly, cou n sel’ s m oti on f or leav e to w i t hdr aw i s G RA N TE D , c o uns e l i s e xc us e d f r o m f ur t he r r e s po ns ibi l i t i e s he r e i n, a n d th e A P P E A L S A R E D IS M IS S E D
. S ee5 T H C IR . R. 42. 2. Case: 09-30702 Document: 00511090583 Page: 2 Date Filed: 04/23/2010
_________________________________________ 

 

 

Order Michigan Supreme Court

Lansing, Michigan 

November 17, 2006 Clifford W. Taylor,

 Chief Justice 

132364 Michael F. Cavanagh 

Elizabeth A. Weaver 

Marilyn Kelly 

Maura D. Corrigan 

Robert P. Young, Jr. _________________________________________ Stephen J. Markman,

 Justices 

IN RE EMMANUEL THOMAS BULLOCK and 

DEMONTE LAMAR BULLOCK, Minors. 

_________________________________________ 

DEPARTMENT OF HUMAN SERVICES,

Petitioner-Appellee, 

v SC: 132364 

 COA: 267910

 Genesee CC

 Family Division: 2000-112736-NA 

WYKISHA TYANE BULLOCK,

Respondent-Appellant, 

and 

CLARENCE ARTHUR WILLIAMS, JR. and

CHACOBRON LAMON DYE, 

Respondents. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the October 3, 2006 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court. 

s1114 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

November 17, 2006 

 Clerk
Office of Compensation Analysis and Support 

Program Evaluation Report

Document Number: 

OCAS-PER-010 

Effective Date: 4/13/2007 

Revision No. 0

The Effect of Rocky Flats Neutron Dose Reconstruction Project 

Data Page 1 of 2 

Author: Signature on file Date: 4/13/2007 David Allen, Dose Reconstruction Team Leader 

Approval: Signature on file Date: 4/13/2007 J.W. Neton, Associate Director for Science 

Supersedes: None 

ISSUE 

AUTHORIZATION 

DATE 

EFFECTIVE 

DATE 

REV. 

NO. DESCRIPTION 

4/13/2007 4/13/2007 0 

New document to report the impact of data 

received from the Rocky Flats Plant Neutron 

Dose Reconstruction Project. 

1.0 Description

Neutron doses at Rocky Flats were re-evaluated as part of the Rocky Flats Neutron Dose 

Reconstruction Project (NDRP). These records were provided to OCAS as part of the individual 

dosimetry records. The application of the NDRP data to dose reconstructions is described in 

ORAUT-OTIB-0050, Rev. 00. 

2.0 Evaluation

Additional neutron doses resulting from the efforts of the Rocky Flats NDRP made it necessary 

to evaluate dose reconstructions that were already completed. The NDRP was initiated to reevaluate some of the original neutron dosimetry results due to issues involving the interpretation 

of the original neutron films. The cases requiring revision concern workers at the plutonium 

production facility for the period from 1952 through 1969, when workers were monitored for 

neutrons using NTA films. The additional neutron dose data may cause an increase or decrease 

in the assigned external dose resulting in a change in the probability of causation (POC). 
Effective Date: 4/13/2007 Revision No. 0 Document No. 

OCAS-PER-010 

Page 2 of 2 

 

3.0 Resolution/Corrective Action

Guidance on the use of the Rocky Flats NDRP data for dose reconstructions can be found in 

ORAUT-OTIB-0050 Rev. 00, issued December 13, 2005. All dose reconstructions for the Rocky 

Flats plant completed after August 31, 2005 already include the NDRP data, but the previously 

completed claims must be re-evaluated. The ORAU team conducted a query of previously 

completed claims for the Rocky Flats Plant whose probability of causation was less than 50% 

and NDRP data was obtained. The query identified 98 such claims. Six of these were 

subsequently returned to OCAS for other reasons. These will be revised using the NDRP data. 

Four claims had already been evaluated for a change to lymphoma target organ (OCAS-PER009) and resulted in a POC greater than 50%. 

The remaining 88 claims were re-evaluated using the NDRP data and currently approved 

procedures. All 88 claims remained below 50% POC. The POC increased in 21 of these cases 

and decreased in the remaining 67 cases. The decreases were primarily the result of reducing 

overestimating assumptions previously used. An itemized list has been provided to DOL 

containing the final evaluation result for each of the 88 claims. 

4.0 Reference

1) ORAU Team, Technical Information Bulletin: Use of Rocky Flats Neutron Dose 

Reconstruction Project Data in Dose Reconstructions, ORAUT-OTIB-0050 Rev 00 

(12/13/2005).
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5927 Introduced in House (IH)]

<DOC>

115th CONGRESS
  2d Session
                                H. R. 5927

   To amend the Public Health Service Act to expand, intensify, and 
coordinate research and other activities of the National Institutes of 
Health with respect to prenatal opioid exposure and neonatal abstinence 
                               syndrome.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 23, 2018

  Mr. Soto (for himself and Mr. Fitzpatrick) introduced the following 
    bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
   To amend the Public Health Service Act to expand, intensify, and 
coordinate research and other activities of the National Institutes of 
Health with respect to prenatal opioid exposure and neonatal abstinence 
                               syndrome.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Neonatal Abstinence Syndrome Best 
Practice Act''.

SEC. 2. RESEARCH ON PRENATAL OPIOID EXPOSURE AND NEONATAL ABSTINENCE 
              SYNDROME.

    Part B of title IV of the Public Health Service Act is amended by 
inserting after section 409J (42 U.S.C. 284q) the following new 
section:

``SEC. 409K. PRENATAL OPIOID EXPOSURE AND NEONATAL ABSTINENCE SYNDROME.

    ``(a) Research.--The Director of NIH shall expand, intensify, and 
coordinate research and other activities of the National Institutes of 
Health with respect to the prevention, identification, and treatment of 
prenatal opioid exposure and neonatal abstinence syndrome. Such 
research and activities shall include the evaluation of treatment 
options, including with respect to--
            ``(1) the impact on short-term and long-term clinical 
        outcomes and costs of pharmacological and non-pharmacological 
        treatment options for infants with opioid withdrawal syndrome; 
        and
            ``(2) innovative care models to transition mothers and 
        babies affected by such exposure and syndrome out of the 
        hospital through outpatient follow-up programs and other 
        interdisciplinary post-discharge programs.
    ``(b) Best Practices.--Based on the research and activities 
conducted pursuant to subsection (a), the Director of NIH shall--
            ``(1) establish, and update as necessary, best practices 
        for screening and treating pregnant women for opioid use 
        disorder and for screening for neonatal abstinence syndrome and 
        opioid withdrawal syndrome among infants exposed to opioids 
        during pregnancy; and
            ``(2) disseminate such best practices to interested 
        stakeholders.''.
                                 <all>
```
AGENDA

Advisory Board on Radiation and Worker Health 

Teleconference Meeting of the 

SEC Issues Work Group

May 13, 2011

Conference Call Number: 1-866-659-0537

Participant Pass Code: 9933701

10:00 a.m. (Eastern Time) Welcome and roll-call/introductions 

Work Group Discussion

1. DCAS presentation of revised GE Evendale SEC Petition Evaluation 

2. WG discussion and recommendation

Adjourn
EXHIBIT 23

INDEPENDENT AUDITORS' CONSENT

The Board of Directors
Spalding Holdings Corporation
Chicopee, Massachusetts

We consent to the incorporation by reference in Spalding Holdings  Corporation's
Registration  Statements No.  333-11340 on Form S-8, No.  333-20463 on Form S-8,
and No.  333-31154  on Form S-8 of our report  dated March 30, 2001 appearing in
this  Annual  Report  on  Form  10-K  of  Spalding   Holdings   Corporation  and
subsidiaries for the year ended December 31, 2000.

DELOITTE & TOUCHE LLP

Hartford, Connecticut
March 30, 2001
IN THE

TENTH COURT OF APPEALS

No. 10-11-00312-CV

THE CITY OF COLLEGE STATION, TEXAS,

Appellant

v.

RACHEL RAHN,

Appellee

From the 361st District Court

Brazos County, Texas

Trial Court No. 09-000656-CV-361

MEMORANDUM OPINION

The City of College Station appealed the trial court’s order denying its plea to the 

jurisdiction to the original petition of appellee, Rachel Rahn, and to the plea of 

intervention of appellees Charles and Lisa Walters. The City has now filed a motion to 

dismiss its appeal stating that the parties have fully settled all issues in dispute. All 

appellees do not oppose the City’s motion.
City of College Station v. Rahn Page 2

Accordingly, the City’s motion to dismiss is granted and this appeal is dismissed. 

See TEX. R. APP. P. 42.1(a).

TOM GRAY

Chief Justice

Before Chief Justice Gray,

Justice Davis, and

Justice Scoggins

Appeal dismissed

Opinion delivered and filed December 21, 2011

[CV06]
EXHIBIT
31




CERTIFICATION
PURSUANT TO SECTION 302




I, Pavel
Alpatov, Chief Executive Officer and Chief Financial Officer of Innovative
Wireless Technologies, Inc., certify that:




1. I have
reviewed the attached report on Form 10-Q.




2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;




3. Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;




4. I am
responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules) for the registrant and have:




a)
designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to me by others within those entities, particularly during the
period in which this report is being prepared;




b)
designed such internal control over financial reporting to provide reasonable
assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally
accepted accounting principles;




c)
evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report my conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluations; and




d)
Disclosed in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and




5. I have
disclosed, based on my most recent evaluation, to the registrant's auditors and
the audit committee of registrant's board of directors (or persons performing
the equivalent functions):




a) all
significant deficiencies in the design or operation of internal controls which
could adversely affect the registrant's ability to record, process, summarize
and report financial data and have identified for the registrant's auditors any
material weaknesses in internal controls; and




b) any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant's internal controls.




Date:
      May 17, 2010
              
              By:
              /s/
      Pavel AlpatovPavel
      AlpatovIts:
              President
      and Director andChief
      Financial OfficerPrincipal
      Accounting Officer
EX-10.9



 Exhibit 10.9 
  

			
	



	  	 ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM

DIVISION OF BUSINESS AND FINANCE
  

SECTION A: CONTRACT AMENDMENT


  

							
	1. AMENDMENT #	  	2. CONTRACT #:	  	3. EFFECTIVE DATE OF AMENDMENT:	  	4. PROGRAM
				
	8	  	YH14-0001-07	  	March 1, 2015	  	DHCM - ACUTE

  

	5.	CONTRACTOR NAME AND ADDRESS: 

 Health Choice Arizona 

410 N. 44th Street, Suite 900 

Phoenix, AZ 85008 
  

	6.	PURPOSE: To amend the Contract for the period March 1, 2015 through September 30, 2015 and to amend Section C, Definitions, Section D, Acute Care Program Requirements, and Section F, Attachments.


  

	7.	THE ABOVE REFERENCED CONTRACT IS HEREBY AMENDED AS FOLLOWS: 

  

	 	•	 	Section C, Definitions 

  

	 	•	 	Section D, Acute Care Program Requirements 

  

	 	•	 	Section D updated throughout to include: 

  

	 	•	 	CMS issued contract requirements for Managed Care Contract compliance; and 

  

	 	•	 	Language revisions to align with AZ HB 2667: Persons with Disabilities. Laws 2014, Chapter 215. 

  

	 	•	 	Other Revisions: 

  

	 	•	 	Paragraph, Staff Requirements and Support Services 

  

	 	•	 	Paragraph, Medical Management 

  

	 	•	 	Paragraph, Subcontracts 

  

	 	•	 	Paragraph, Claims Payment/Health Information System 

  

	 	•	 	Paragraph, Coordination of Benefits/Third Party Liability 

  

	 	•	 	Paragraph, Systems and Data Exchange Requirements 

  

	 	•	 	Paragraph, Pending Legislation/Other Issues 

  

	 	•	 	Section F, Attachments 

 Attachment F3, Contractor Chart of Deliverables 

 

	7.	EXCEPT AS PROVIDED FOR HEREIN, ALL TERMS AND CONDITIONS OF THE ORIGINAL CONTRACT NOT HERETOFORE CHANGED AND/OR AMENDED REMAIN UNCHANGED AND IN FULL EFFECT. 


IN WITNESS WHEREOF THE PARTIES HERETO SIGN THEIR NAMES IN AGREEMENT 

 

			
	9. SIGNATURE OF AUTHORIZED REPRESENTATIVE:	  	10. SIGNATURE OF AHCCCS CONTRACTING OFFICER:
		
	 /s/ Mike Uchrin
	  	 /s/ Michael Veit

	TYPED NAME:            MIKE UCHRIN	  	TYPED NAME:             MICHAEL VEIT
		
	TITLE:         CHIEF EXECUTIVE OFFICER	  	TITLE: CONTRACTS AND PURCHASING ADMINISTRATOR
		
	DATE:                           1/27/15	  	DATE:                           JAN 9 2015








 See Exhibit 10.XX for full current amended text of AHCCCS Contract.
Exhibit 31.2
                                  CERTIFICATION

I, Stephen D. Replin, certify that:

1. I have reviewed this annual report on Form 10-KSB of Monet Entertainment
Group Ltd.

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the small business
issuer as of, and for, the periods presented in this report;

4. The small business issuer's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e) for the small business issuer and
have:

a) Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the small business issuer, including its
consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;

c) Disclosed in this report any change in the small business issuer's internal
control over financial reporting that occurred during the small business
issuer's most recent fiscal quarter (the small business issuer's fourth fiscal
quarter in the case of an quarterly report) that has materially affected or is
reasonably likely to materially affect, the small business issuer's internal
control over financial reporting; and

5. The small business issuer's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the small business issuers auditors and the audit committee of
small business issuer's board of directors (or persons performing the equivalent
functions):

a) All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the small business issuer's ability to record,
process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the small business issuer's internal
control over financial reporting.

Date: March 2, 2005

/s/ Stephen D. Replin
---------------------
Stephen D. Replin
Chief Financial Officer
QuickLinks
 -- Click here to rapidly navigate through this document









































 
 

  Exhibit 4.8    
    




 

 






			
	



 	 	



 



 

 December 23,
2015 


VIA SEDAR — PROJECT #02429893  


Alberta Securities Commission (as Principal Regulator under National Policy 11-202)

British Columbia Securities Commission

Financial and Consumer Affairs Authority of Saskatchewan

The Manitoba Securities Commission

Ontario Securities Commission

Autorité des marchés financiers

Nova Scotia Securities Commission

Prince Edward Island Superintendent of Securities

New Brunswick Financial and Consumer Services Commission

Superintendent of Securities, Service Newfoundland and Labrador

Northwest Territories Superintendent of Securities

Yukon Superintendent of Securities

Nunavut Superintendent of Securities 


Dear
Sirs: 

 






			
	Re:	 	TransCanada Corporation

Final Short Form Base Shelf Prospectus



 

 We
refer to the final short form base shelf prospectus dated December 23, 2015 (the "Prospectus") of TransCanada Corporation
(the "Corporation") relating to the offering by the Corporation of common shares, first preferred shares, second preferred shares and
subscription receipts having an aggregate offering price of up to $2,000,000,000. 


We
hereby consent to the references to our firm name under the headings "Enforceability of Civil Liabilities", "Legal Matters", "Interest of Experts" and "Documents Filed as Part of the Registration
Statement" in the Prospectus and to the use of our opinion under the heading "Enforceability of Civil Liabilities" in the Prospectus. 


We
confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that are derived from our opinion
referred to therein or that are within our knowledge as a result of the services we performed in connection with such opinion. 

 






			
	 	 	Yours truly,
	

 	
 	
 
	 	 	(signed) "Blake, Cassels & Graydon LLP"



 

  









  


 












QuickLinks



Exhibit 4.8
Exhibit 32.1

 

**CERTIFICATION**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEYACT OF 2002**

 

     I, G. Reed Petersen, ChiefExecutive Officer and Chief Financial Officer of Sears Oil & Gas Corporation (the "Company") certify that:

 

     1. I have reviewed the quarterlyreport on Form 10-Q of Sears Oil & Gas Corporation;

 

     2. Based on my knowledge, thisquarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the periodcovered by this quarterly report; and

 

     3. Based on my knowledge, thefinancial statements, and other financial information included in this amended quarterly report, fairly present in all materialrespects the financial condition, results of operations and cash flows of the Company as of, and for, the period presented in thisamended quarterly report.

 

Date:  February 14, 2013

 

 

 

/s/ G. Reed Petersen

__________________

G. Reed Petersen,

Chief Executive Officer

Chief Financial Officer
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

LOUIS DIOR AMIR,

Petitioner

v.

JOHN A. VASKOV, ESQUIRE DEPUTY 

PROTHONOTARY OF THE SUPREME 

COURT OF PENNSYLVANIA IN HIS 

OFFICIAL CAPACITY,

Respondent

:

:

:

:

:

:

:

:

:

:

:

:

:

:

No. 171 MM 2018

ORDER

PER CURIAM

AND NOW, this 18th day of January, 2019, the Application for Leave to File 

Original Process is GRANTED, and the Petition for Writ of Mandamus is DENIED.